ArticleScientific reports2025
The demographic characteristics and prognosis of acute myeloid leukemia with t(3;3)/inv(3) in the united states: a SEER-based study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic nomograms for predicting overall and cancer-specific survival in acute erythroid leukemia: a SEER-based study.Discover oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acute myeloid leukemia (AML) with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) is a rare subtype of acute myeloid leukemia with a poor prognosis. Research on the demographic characteristics and clinical outcomes of AML patients with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) is limited. All AML patients diagnosed with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) between 2000 and 2021 from SEER (Surveillance, Epidemiology, and End Results Program) database were included in this study. Survival analysis was performed using the Kaplan-Meier method. The log-rank test was used to analyze the significance of differences between overall survival (OS) and cancer-specific survival (CSS). Due to being a retrospective study, the limited amount of baseline characteristics available, and the missing information on treatments and recurrence, the provided dataset is not exactly representative for the US population. The median age of the total 90 AML patients with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) was 65(49-74) years old. Among them, 57.78% were married and non-Hispanic whites accounted for 74.44%. 84.44% of the patients received chemotherapy. The median OS was 8 months, and the median CSS was 10 months. The 5-year survival rate for OS was 15.29% (95%CI:7.98-24.78%), and 20.05% (95%CI:10.69-31.51%) for CSS. The OS and CSS of patients above 60 years were inferior to those of patients under 60 years. Single (never-married) patients had better OS and CSS than those with other marital status. Age and marital status at diagnosis were independent influencing factors for OS and CSS based on the multivariate COX regression analysis. AML with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) mostly occurs in adults and has poor clinical outcomes with worse OS and CSS, especially in the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.